Monoclonal Antibodies Market for Cancer Treatment Tops $73 Billion: Kalorama Information
Monoclonal antibodies are finding wide application in many areas of medicine and biologic science.
ARLINGTON, Va., Nov. 21, 2022 /PRNewswire-PRWeb/ -- The global market for monoclonal antibodies in cancer treatment topped $73.1 billion in 2022, and is forecast to increase to $94.8 billion in 2027. This is the finding of Kalorama Information's recent report on Precision Cancer Therapeutics Market, 2022. Kalorama Information is a medical market research firm that has been covering pharma and in vitro diagnostics (IVD) for two decades, and is owned by Science and Medicine Group.
Monoclonal antibodies are immune system proteins that are created in the lab. Monoclonal antibodies are homogeneous populations of identical antibody molecules produced by specialized tissue cell culture lines. The procedure uses cell fusion techniques and standard in vitro tissue culture systems. The two essential biologic components are immunized mice or rats and myeloma tumor cell lines, which are of lymphoid origin.
Monoclonal antibodies are finding wide application in many areas of medicine and biologic science. Thousands of monoclonal antibodies have been made against many different types of antigens. Monoclonal antibodies have begun to replace conventional antibodies in blood banking and are used in the identification of organisms in the bacteriology laboratory. Monoclonal antibodies have also been extensively used in radioimmunoassay to measure serum levels of various substances.
Among monoclonal products are the following:
"Avastin (bevacizumab)"
Avastin is designed to inhibit VEGF, a protein that plays an important role in tumor angiogenesis and maintenance of existing tumor vessels. Avastin contains the active ingredient bevacizumab, which binds VEGF and prevents the interaction of VEGF with receptors on the surface of endothelial cells.
Avastin is most notably approved for the treatment of metastatic colorectal cancer. The FDA approved Avastin in February 2004 for the first line treatment in combination with intravenous 5-Fluorouracil-based chemotherapy treatment. Avastin received approval for the same indication in the European Union in January 2005 after Roche submitted a marketing authorization for the product in December 2003. Avastin was also approved in June 2006 in the United States for second line treatment for colorectal cancer.
Other approvals for Avastin have followed, including approvals for brain, kidney, lung, ovarian and other cancers.
"Blincyto (blinatuomab)"
Blincyto offered by Amgen is a monoclonal antibody that is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia in the first or second complete remission with minimal residual disease. The product was FDA approved in February 2018.
"Darzalex (daratumumab)"
Darzalex injection is a CD38-directed cytolytic antibody. CD38 is a surface protein expressed across multiple myeloma cells and not limited to a specific disease stage. It is indicated for use as a combination therapy for multiple myeloma, and a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy.
In 2012, Janssen Biotech and Genmab A/S entered an agreement for Janssen to undertake the development, commercialization and manufacturing. Approved by the FDA originally in November 2015, Darzalex has many more indication approvals.
"Erbitux (cetuximab)"
Erbitux is a monoclonal antibody designed to target and block the EGFR, which is expressed on the surface of certain cancer cells. Erbitux binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
About Kalorama Information:
Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.
Media Contact
Daniel Granderson, Kalorama Information, (703) 783-1721, [email protected]
SOURCE Kalorama Information
Share this article